SCHEMBL20122931

SCHEMBL20122931

Cc1nccc2c1[nH]c1c(-c3ccc(OCc4ccc5ccccc5n4)cc3)cc(Cl)cc12

nearest known ligand 0.52

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 15/20 0.52
ALOX5AP P20292 1/20 0.52
LGALS3 P17931 1/20 0.47
PDE4D Q08499 1/20 0.47
HTR2B P41595 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29756400 1.00 PDE10A (0.52) PDE10AALOX5APLGALS3PDE4DHTR2B
SCHEMBL30664195 0.91 CYSLTR1 (0.47) PDE10AALOX5AP
SCHEMBL20122906 0.91 CYSLTR1 (0.47) PDE10AALOX5AP
SCHEMBL20122752 0.86 PDE10A (0.43) PDE10AALOX5AP
SCHEMBL30664230 0.86 MAOA (0.61) PDE10AALOX5AP
SCHEMBL20123044 0.86 MAOA (0.61) PDE10AALOX5AP
SCHEMBL30664311 0.85 MAOA (0.46)
SCHEMBL20123078 0.85 MAOA (0.46)
SCHEMBL20123027 0.84 MAOA (0.46) PDE10A
SCHEMBL30664215 0.84 MAOA (0.46) PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 PDE10A 415/4885ALOX5AP 1606/4885LGALS3 1133/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 PDE10A 415/4885ALOX5AP 1606/4885LGALS3 1133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.